I wonder if any gamblers noticed my post 334 on the GMC thread yesterday.
It looks as though bottom fishing can sometimes pay off.

squidd....at close US..$6.97/+9.5%

Vivid blue again! And some heavy selling; maybe someone wants these shares.
sQd.

Another day of heavy selling and hefty price rise. Everyone on this BB should now be showing a healthy profit, especially those who bought into the second crash - it certainly brightened up my ISA. Interesting to see what Fri 13th brings - maybe a revelation.
sd.

squidd ELA still looking good on the recovery play front I see I have added KUJ to the recovery list of OSH APH ELA and others we have and along with that UNG is worth a serious look now with bottomed price at below price to book of 1.

The wife is watching casualty and I'm scouring the internet and I'm baffled. According to PUBMED the US National Library of Medicine, the disease for which ELA is taking all the flak - PMLE - was first disclosed in 1958, about 40 years before ELA came on the scene with their new drugs, so how can they be blamed. Are there any medics who can explain.
sd.

Live webcast of today's ELA A.G.M. now playing. Access via elan.com.

Much of the discussion focussed on the latest drugs and directors expressed cautious optimism about the future in this morning's question time at the AGM. They revealed that there are around 100,000 MS sufferers in the US who are currently recieving no medication, and the talk was not of whether, but when their flagship drug Tysabri would return to the market.

agm this morning....excellent news....this is going to go balistic.......sorry....has gone ballistic and the US has even opened yet (pre market +11% and rising!!!!)

I had e-mailed Elan with my query about PMLE [post 31} and had no direct reply, but this was aired in the AGM and the medics put it into perspective - too complex for laymen like me to report here.
Meanwhile they are looking optimistic so far, over on NASDAQ.
sd.

Some new heavyweight board appointments announced today, seem to have brought ELA firmy back onto its recovery course.
sd.

squidd ELA still rising and OSH too so good news all round.

future is looking bright!

PpP: I see that OSH is leading ELA again but allowing for the spread handicap, they are probably neck & neck and both running extremely well.
Some of my TA friends are getting excited about various MA crosses and OBV's for
ELA saying it points to a re-run of last year's big climb. I'm not an astrologist, but would be interested to hear views from any other chartists. Meanwhile, in my view the simple chart and volume are saying it's better than money in the bank, so I'm tempted to dip into my cash pile and add to ELA.

Have sniffed around the RPT crash site to see if there's any worthwile salvage over there but decided to keep away and see what other skeletons might be dragged out.

I am looking very hard at ULT which I think could be a big climber in the NHS health care market. Knowing of your interest in health matters, perhaps see you over there.
sd.

squidd it is neck and neck and with the way they are marking up OSH sometimes on no trades I think they know very positive news is coming with the results next week so will OSH take the lead?

squidd forgot to say some real good news at VLK

suggest you think about getting out temporarily if not already done so due to rumour of new fatality.......the panic may well set in early this afternoon when the US moves....

Wisemove: Thanks for info, have scoured the net in vain for details; fortunately still up on month.
sd.

from another site:

Reuters.com

Elan falls on new report of Tysabri-linked illness
Thu Jun 2, 2005 05:11 AM ET
DUBLIN, June 2 (Reuters) - Shares in Elan Corp. (ELN.I: Quote, Profile, Research) fell as much as 24 percent on Thursday following a report that a fourth patient taking its multiple sclerosis drug Tysabri may have contracted a deadly brain disease.
Elan halted sales of Tysabri on February 28 after a patient died from a rare brain infection, known as PML.

The Boston Globe reported on Thursday that Biogen Idec Inc. (BIIB.O: Quote, Profile, Research) , with whom Elan developed Tysabri, had told the Food and Drug Administration that a fourth patient may have contracted PML.

Shares in Elan dropped to a day low of 4.91 euros and were 15.1 percent lower at 5.35 euros by 0911 GMT.

looks like we'll see a further fall after the US market opens (although the % will have been for the greater part already abosrbed) then a degree of stablization and then a pointer of where we go fom here.

from another site:

Things are not as bad as first thought, so up we go again!

Goodbodys have a buy on Elan:

Elan (Buy, Current Price $6.85)
What is material to Tysabri's progress?
After a day with no communication on speculation around Tysabri, a spokesperson for the FDA would now appear to have confirmed that Elan and Biogen Idec have received a report of a suspected case of PML. Given the lack of response from both Elan and Biogen Idec, we infer that the case referred to has been deemed by all parties involved not to be material to the progress of Tysabri through the approval process. The reference to the Freedom of Information Act in earlier speculation is particularly intriguing though. A Federal body can take 20 days to respond to a request for data under FoI and has the opt-out clause that it will not disclose information that it considers to be commercially sensitive. From this, the inference of a fourth potential case (if from an FoI-driven source) could possibly be from data lodged with the FDA some time over the past few weeks. We consider it inconceivable that, if material, that data were not disclosed to the market during this period. Given the recent corporate action (debt retirement) and bullish stance on Tysabri, both Elan and Biogen Idec's definition of "material" will have been closely scrutinised by all parties in the review process. The inference, therefore, is that if there is a fourth suspected case of PML, it has been agreed by all parties involved to be, as yet, immaterial to the progress of Tysabri through the review process. Undoubtedly, it will be discussed at the Biogen Idec AGM today (15:00 Dublin/London).

Good luck/dyor

www.ninds.nih.gov/disorders/pml
The US National Institute for Neurological Disorders, puts into perspective the rare brain disease that has been linked to ELA's flagship drug. The impression given is that it is much less rare now, being an opportunistic disease that can take hold in the presence of various immuno-suppressor drugs, AIDS victims being especially vulnerable.
ELA seems to be back on the road to recovery.
sd.